Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Women (NOC)

Ferring

Status and phase

Completed

Phase 2

Conditions

Nocturia

Treatments

Drug: C: Placebo

Drug: B: Desmopressin 25 microgram

Drug: A. Desmopressin 10 microgram

Study type

Interventional

Funder types

Industry

Identifiers

NCT01684800

000029

Details and patient eligibility

About

The purpose of the study is to investigate the efficacy and safety of two different dose levels of desmopressin orally disintegrating tablets against placebo for the treatment of nocturia in adult women during 12 weeks treatment

Enrollment

178 patients

Sex

Female

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Has given written consent prior to any trial-related activity is performed.
Female sex, aged 20 years or older.
At least 2 nocturnal voids every night in a consecutive 3-day period as documented in the diary during the screening period.
Has given agreement about contraception during the trial.

Exclusion criteria

Showing symptoms of any of the following diseases: Interstitial cystitis; Overactive bladder, defined as >6 daytime voids,≥1 urgency episode and ≥1 urge urinary incontinence episode per 24 hours as documented in the 3-day diary period; Severe stress urinary incontinence.
Psychogenic or habitual polydipsia.
Urinary retention or a post void residual volume in excess of 150 mL as confirmed by bladder ultrasound performed after suspicion of urinary retention.
Cancer.
A history of urologic malignancies or a history of cancer which has not been in remission for the last 5 years.
Genito-urinary tract pathology.
Neurogenic detrusor activity.
Suspicion or evidence of heart failure.
Uncontrolled hypertension.
Uncontrolled diabetes mellitus.
Hepatobiliary diseases: Aspartate aminotransferase >80 U/L or alanine aminotransferase >90 U/L; Total bilirubin >1.5 mg/dL.
Renal insufficiency: Serum creatinine level >0.82 mg/dL; Estimated glomerular filtration rate <50 mL/min.
Hyponatraemia: Serum sodium level <135 mEq/L.
Central or nephrogenic diabetes insipidus.
Syndrome of inappropriate antidiuretic hormone.
Obstructive sleep apnea.
Previous desmopressin treatment.
Treatment with another investigational product within the past 3 months.
Concomitant treatment with any prohibited medication.
Pregnancy, breastfeeding, or a plan to become pregnant during the period of the clinical trial.
Alcohol or substance abuse.
A job or lifestyle that may interfere with regular night-time sleep.
A mental condition, lack of decision-making ability, dementia, a speech handicap, or any other reason which, in the judgement of the investigator (sub-investigator), would impair the participation in the trial.